Fresenius Kabi Recalls One Lot of Tyenne Injection 400 mg/20 mL After Glass Particle Detection

Glass particle contamination in a parenteral biologic carries the highest tier of patient risk, and Fresenius Kabi confirmed that exposure on August 10, 2026, when it initiated a nationwide user-level recall of one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL following an internal investigation that identified glass particulates in the product.

The recalled lot, Lot UI070, NDC 65219-594-20, expiring August 2028, was distributed to wholesalers, distributors, and direct customers between March 3 and March 25, 2026. The distribution window means affected units have had more than five months in the supply chain, raising the probability that product reached infusion suites and hospital pharmacies already managing active patient schedules.

Fresenius Kabi's risk statement classifies the hazard as serious: glass particulates in an injectable product can cause local irritation, venous inflammation, vascular occlusion, pulmonary embolism, permanent organ damage, or death. Tyenne is indicated across a broad patient population, adults with rheumatoid arthritis, giant cell arteritis, and COVID-19, as well as pediatric patients aged two and older with polyarticular or systemic juvenile idiopathic arthritis and CAR T cell-induced cytokine release syndrome, meaning the affected lot may have reached immunocompromised and critically ill patients with limited physiological reserve.

For QA directors and plant heads, the contamination mode warrants close attention. Glass particle findings in vial-based injectables typically implicate delamination, vial-to-stopper or vial-to-vial contact during filling, or inadequate 100% visual inspection under 21 CFR Part 211.94 and 211.68 controls. Whether the root cause originates in primary packaging qualification, automated inspection sensitivity settings, or AQL sampling thresholds will determine the corrective scope, none of which Fresenius Kabi has disclosed publicly at this stage.

Healthcare facilities holding any units of Lot UI070 are directed to immediately discontinue distribution, dispensing, and use, and to arrange return through Fresenius Kabi. Distributors carry an obligation to cascade notification to downstream customers. Quality or adverse event reports can be directed to Fresenius Kabi at 1-800-551-7176 or submitted to FDA MedWatch via www.fda.gov/medwatch/report.htm.

The recall is being conducted with FDA knowledge; the agency's classification of this action, and any resulting inspection activity at the Lake Zurich facility, will be a measurable indicator of how regulators assess the adequacy of Fresenius Kabi's particulate matter controls going forward.

Source: U.S. Food and Drug Administration recalls database via FDA.gov RSS Feed, August 11, 2026.